Inebilizumab Biosimilar - Research Grade

Human

CD19

>1mg/ml

Human IgG1 Kappa

Bulk Anti-Human CD19 (SJ25-C1) Antibody (ICH1011), Anti-CD19 (1D3) In Vivo Antibody - Low Endotoxin (ICH1052), Bulk anti-Human CD19 (4G7) Antibody (ICH1237), Anti-Human FMC63 (IB11) Antibody (ICH1258), Tafasitamab Biosimilar - Research Grade (ICH5132), Loncastuximab Biosimilar - Research Grade (ICH5298), Budoprutug Biosimilar - Research Grade (ICH5418), Obexelimab Biosimilar - Research Grade (ICH5719), Tisagenlecleucel Biosimilar - Research Grade (ICH5928)

https://www.imgt.org/mAb-DB/

ICH3002

P15391;P51677

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of inebilizumap, an anti-CD19 antibody, supplied strictly for research use only. It is built around the CD19 target and carries a human IgG1 kappa framework, making it a convenient reference reagent for laboratories studying CD19 biology and B-cell-directed antibody mechanisms. It is not the clinical drug and is not intended for human or veterinary use. Typical research applications include use as a binding and specificity control, as a positive control in CD19 detection or flow-cytometry panels, as a benchmarking tool in ADCC/ADCP assays, and as a starting reagent in antibody-drug-conjugate or effector-function development workflows. The material is offered unconjugated so that users can label, format, or engineer it as needed. Low-endotoxin grades (research grade less than 1 EU/mg; ultra-low grades less than 0.5 EU/mg) support sensitive in-vitro assays and preclinical models, and bulk milligram-to-gram quantities are available for scale-up, assay standardization, and repeated experimental use across a research program. CD19 is a B-lymphocyte-restricted transmembrane glycoprotein of the immunoglobulin superfamily and one of the earliest and most consistently expressed surface markers across B-cell development, from pro-B cells through mature B cells and into most plasmablasts, while being lost on terminally differentiated plasma cells and absent from hematopoietic stem cells. It functions as a positive co-receptor for the B-cell antigen receptor (BCR), assembling with CD21, CD81, and CD225 to lower the threshold for antigen-driven B-cell activation and to amplify BCR signaling through recruitment of PI3K and downstream survival and proliferation pathways. Because its expression is broad and B-cell-lineage-specific, CD19 is a key marker for identifying and quantifying B cells and a validated target for depleting antibody and cell-based therapies directed at B-cell malignancies and autoimmune disease.

B4, CVID3, Leu-12

Detects human CD19

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.